Martin J. Duvall

Martin J. Duvall is a declared insider at 2 companies; the most frequent names are Ariad Pharmaceuticals Inc and Forte Biosciences, Inc. Over a trading history stretching from 20 March 2013 to 28 May 2019, the count stands at 32 filings.

In open-market terms, that means 1 purchase worth €19k on one side and 9 sales worth €313k on the other. Sales outweigh purchases by €293k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 5 share grants and 15 option exercises. So far in 2019, the count stands at 1 purchase and no sales.

The newest entry dates from 29 May 2019: an open-market purchase of €19k, in Forte Biosciences, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.